EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

2024.04.25
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Ke Xiaoyan from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Hu Kai from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.
Professor Yin Wu: Diagnosis and Treatment Evaluation of Multiple Myeloma: Examination and Application

Professor Yin Wu: Diagnosis and Treatment Evaluation of Multiple Myeloma: Examination and Application

2024.04.25
Every March is the international "Myeloma Awareness Month". In order to better serve patients with multiple myeloma, recently, the Hematology Department of Beijing Chaoyang Hospital, affiliated with Capital Medical University, held a series of activities for Multiple Myeloma Awareness Month. The aim is to enhance public awareness of multiple myeloma through a combination of online and offline approaches, calling for attention to the new trend of long-term survival in multiple myeloma and establishing a new concept of comprehensive management throughout the disease course. During the event, Professor Yin Wu from Beijing Chaoyang Hospital, affiliated with Capital Medical University, shared the exciting content titled "Diagnosis and Treatment Evaluation of Multiple Myeloma: Examination and Application". Below is a summary of the presentation.
EBMT China’s Voice | Professor Chunfu Li ‘s Team: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections in Patients with Beta-Thalassemia Major Treated with Different Sources of Stem Cell Transplantation

EBMT China’s Voice | Professor Chunfu Li ‘s Team: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections in Patients with Beta-Thalassemia Major Treated with Different Sources of Stem Cell Transplantation

2024.04.24
Allogeneic hematopoietic stem cell transplantation (HSCT) is the classical treatment for curing beta-thalassemia major. With the continuous maturity of HSCT technology and supportive therapy over the past two decades, the choice of HSCT methods has expanded from classical matched sibling donor transplantation to matched unrelated donor transplantation and haploidentical transplantation. The commonly used stem cell types have also gradually transitioned from bone marrow hematopoietic stem cells to mobilized peripheral blood stem cells. Additionally, cord blood stem cells from related or unrelated donors have been widely used. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom. The conference focused on the latest advances in stem cell transplantation and cell therapy, driving towards better clinical outcomes for patients with hematological diseases and hematologic malignancies. At the meeting, Professor Chunfu Li from the Southern Chunfu (Pediatric) Hematology Research Institute, High-performance Medicine (Hematology) Guangdong Research Center, reported a clinical study comparing immune reconstitution, graft-versus-host disease (GVHD), and viral infections in patients with beta-thalassemia major treated with stem cell transplantation from different sources. The following is a compiled summary of the content for readers' enjoyment.
Professor Zhongxing Jiang: Focusing on the diagnosis and treatment of chronic disease-related anemia to improve patient quality of life | The 19th National Conference on Red Blood Cell Diseases (Anemia) by the Chinese Medical Association

Professor Zhongxing Jiang: Focusing on the diagnosis and treatment of chronic disease-related anemia to improve patient quality of life | The 19th National Conference on Red Blood Cell Diseases (Anemia) by the Chinese Medical Association

2024.04.24
Chronic disease-related anemia, as one of the most common types of anemia, is the most common type of anemia among hospitalized patients and elderly individuals. Chronic disease-related anemia is usually accompanied by underlying diseases, with complex causes and diverse symptoms, distributed across multiple departments. Clinical doctors should pay sufficient attention to it in order to achieve better treatment outcomes. At the recent 19th National Conference on Red Blood Cell Diseases (Anemia) hosted by the Chinese Medical Association, Professor Zhongxing Jiang from The First Affiliated Hospital of Zhengzhou University shared the progress and prospects of the diagnosis and treatment of chronic disease-related anemia with Oncology Frontier - Hematology Frontier.
EBMT China’s Voice | Professor Yue Lu: Haploidentical Hematopoietic Stem Cell Transplantation Using Non-Direct Related Donors vs. Direct Related Donors – Similarity in Efficacy and Safety

EBMT China’s Voice | Professor Yue Lu: Haploidentical Hematopoietic Stem Cell Transplantation Using Non-Direct Related Donors vs. Direct Related Donors – Similarity in Efficacy and Safety

2024.04.23
In recent years, haploidentical donor hematopoietic stem cell transplantation has gradually been developed in malignant hematologic tumors, greatly solving the problem of previous donor shortages. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, the third-largest city in the UK. At this EBMT Annual Meeting, Professor Yue Lu from Lu Daopei Hospital reported on a latest clinical research result. The study confirmed that in haploidentical hematopoietic stem cell transplantation, using non-direct related donors can be comparable to direct related donors in terms of efficacy and safety. This also provides further evidence to expand the range of selectable donors in clinical practice. Our journal invited Professor Yue Lu to share the important results and clinical significance of this study with colleagues.
EBMT China’s Voice | Professors XiaoyanKe and KaiHu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

EBMT China’s Voice | Professors XiaoyanKe and KaiHu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

2024.04.23
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.
Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference

Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference

2024.04.23
From March 23rd to 24th, 2024, the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference, hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, and co-organized by the First Affiliated Hospital of Soochow University, was successfully held in Suzhou, Jiangsu Province, China. Numerous hematological experts and scholars from China and abroad engaged in academic exchanges on experimental diagnosis in the field of hematological diseases and the latest developments in rare blood diseases through academic presentations and thematic discussions.During the conference, Professor Bing Xiang from West China Hospital of Sichuan University delivered an insightful presentation titled "Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma." In this article, we summarize the main points of the presentation for the benefit of our readers.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

2024.04.10
In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This collaborative research not only offers new hope for R/R DLBCL patients but also showcases the pioneering spirit driving advancements in oncology. By providing valuable insights into allo-HSCT's potential, Professor Huang and his team contribute significantly to the evolving landscape of cancer treatment, highlighting the importance of innovation and teamwork in improving patient care.